4-苯基丁酸_索莱宝|主营生物科研试剂&抗体|蛋白|多肽|试剂盒|专业定制化服务平台-Solarbio【网上商城】

产品中心

生化试剂

抗生素维生素动植物激素酸&盐&胺糖及衍生物脂质＆脂肪酸衍生物核酸&核苷酸及衍生物氨基酸&蛋白质酶&辅酶表面活性剂&去垢剂&螯合剂氘代试剂稳定同位素反应底物其他生化试剂通用缓冲液

蛋白与免疫

重组蛋白蛋白提取/定量免疫佐剂细胞全蛋白抗原蛋白电泳抗体标记试剂盒其它实验试剂

多肽

封闭肽化妆品肽目录肽定制肽

抗体

一抗二抗内参抗体细菌抗体标签抗体 RNA抗体植物抗体小分子抗体病毒抗体

ELISA

人小鼠大鼠通用其他种属未包被试剂盒抗体对 Elisa辅助试剂

流式分析

流式辅助试剂

分子生物学

核酸提取/纯化 PCR/qPCR 分子克隆相关酶核酸电泳重组克隆表达质粒分子杂交分子生物学辅助试剂 MBI原装

细胞生物学

细胞系（株）细胞器提取试剂盒细胞培养基Kit 细胞培养与消化细胞分离液细胞生长因子细胞检测鲎试剂植物培养

小分子化合物

迷你化合物Kit 抑制剂＆拮抗剂＆激动剂疾病造模剂明星产品 Peptides 化合物库 PROTAC/蛋白降解靶向嵌合分子同位素标记物氨基酸及其衍生物 Anti-infection/抗感染糖类及其衍生物维生素及其衍生物助溶剂&增溶剂染料&探针反应底物&理化检测实验常用溶液

生化试剂盒

氮代谢系列脂肪酸代谢系列糖类代谢系列其他生化系列氧化还原系列蛋白及酶类系列能量代谢系列

染色试剂

染色原料荧光染色液 HE染色液组织染色液植物染色液酶类染色液特殊细胞染色液胞内组分染色液微生物染色液辅助试剂组织切片制备试剂

分析标准品

分析对照品紫外分光标准品可溯源标准品对照药材仪器检定标液单标溶液混标套装液相色谱用试剂盒分析辅助试剂质控标样/基质标物代销产品

微生物培养

菌株培养基基础培养基原料培养基添加剂发酵专用产品酵母缺陷型培养基其他微生物培养基微生物辅助试剂 OXOID原装

层析介质

预装柱填料

磁珠

纯化磁珠免疫沉淀纳米抗体磁珠基础磁珠

仪器、耗材

基础耗材培养耗材 PCR&分子生物学耗材 WB&免疫耗材药敏纸片病理制片耗材安全防护耗材其他耗材层析用耗材实验仪器

纳米材料

石墨/石墨烯类石墨烯碳纳米材料无机纳米材料分子筛金属纳米材料其它纳米材料

化学合成

分子砌块 PEG衍生物金属材料

SKU	北京总部	北京海淀	武汉	广州
IP5000-100mg	咨询	咨询	咨询	咨询
IP5000-500mg	咨询	咨询	咨询	咨询

SKU

北京总部

北京海淀

武汉

广州

IP5000-100mg

咨询

IP5000-500mg

咨询

CAS	No.1821-12-1
中文名称	4-苯基丁酸
英文名称	4-Phenylbutyric Acid
别名	4-苯基丁酸;Octyloniumbromide;SP63;苯丁酸;4-苯丁酸;苯基丁酸;4-Phenylbutanoicacid;4-PBA
分子式	C₁₀H₁₂O₂
分子量	164.2
溶解性	Soluble in DMSO ≥200mg/mL
纯度	≥98%
外观(性状)	White to off-white Solid
储存条件	Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
EC	EINECS 217-341-8
MDL	MFCD00004403
SMILES	C1=CC=C(C=C1)CCCC(=O)O
InChIKey	OBKXEAXTFZPCHS-UHFFFAOYSA-N
InChI	InChI=1S/C10H12O2/c11-10(12)8-4-7-9-5-2-1-3-6-9/h1-3，5-6H，4，7-8H2，(H，11，12)
PubChem CID	4775
靶点	HDAC;ER Stress inhibitor
通路	DNA Damage/DNA Repair;Epigenetics;NF-κB;ER Stress
背景说明	4-Phenylbutyric Acid是一种组蛋白去乙酰化酶 (HDAC) 和内质网应激 (ER) 抑制剂。
生物活性	4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress， used in cancer and infection research.[1-3]
In Vitro	4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC， inhibits the growth of NSCLC Cell Lines at 2 mM. Benzenebutyric acid in combination with ciglitizone results in enhanced growth arrest of cancer cells[1]. 4-Phenylbutyric acid (0-5 mM) inhibits ASFV infection in a dose-dependent manner. Benzenebutyric acid also inhibits the ASFV late protein synthesis and disrupts the virus-induced H3K9/K14 hypoacetylation status. Benzenebutyric acid and enrofloxacin act synergistically to abolish ASFV replication[2]. Addition of bafilomycin A1 results in accumulation of LC3II， whereas 4-Phenylbutyric acid substantially reduces this accumulation. LPS decreases the level of p62， whereas Benzenebutyric acid reverses this decrease upon LPS stimulation for 48 h. The percentage of cells with LPS-induced AVOs is increased at 48 h， whereas 4-Phenylbutyric acid significantly reduces this percentage. Specifically， the percentage of cells with AVOs decreases from 61.6% to 53.1% upon Benzenebutyric acid treatment， supporting that 4-Phenylbutyric acid inhibits LPS-induced autophagy. As a positive control for autophagy inhibition， bafilomycin A1 is used. The percentage of cells with LPS-induced AVOs is reduced by bafilomycin A1 treatment. The decreased OC area and fusion index observed after Benzenebutyric acid treatment are not observed with knockdown of ATG7. Inhibition of NF-κB using BAY 11-7082 and JSH23 reduce the LC3 II level upon LPS stimulation and completely abolish the inhibitory effect of Benzenebutyric acid on LPS-induced effects[3].
In Vivo	LPS induces significant bone loss and decreases bone mineral density (BMD)， bone volume (BV/TV)， and trabecular thickness (Tb. Th) compared with PBS alone， whereas trabecular space (Tb. Sp.) is increased. 4-Phenylbutyric acid (4-PBA) attenuates LPS-induced bone loss. Treatment with 4-Phenylbutyric acid increases BMD， BV/TV， and Tb. Th. compared with LPS alone， in addition to decreasing the enlargement of Tb. Sp.， but no change is observed when mice are treated with Benzenebutyric acid alone. OC.S/BS as assessed by TRAP staining is also significantly reduced when Benzenebutyric acid is administered to LPS-treated mice. However， OC.N/BS tends to decrease， although not with statistical significance， when mice are treated with Benzenebutyric acid and LPS. These results indicate that the effect of Benzenebutyric acid on OC from LPS-treated mice is to reduce its size rather than number. Consistent with these findings， a marker of bone resorption in vivo， serum CTX-1 which is elevated by LPS treatment is decreased when Benzenebutyric acid administered to LPS-injected mice. However， co-treatment with Benzenebutyric acid do not significantly affect the levels of serum ALP and osteocalcin， 2 markers of bone formation in vivo， compared with LPS alone. Benzenebutyric acid also reduces the LPS-induced rise in serum MCP-1， indicating that Benzenebutyric acid decreases systemic inflammation induced by LPS[3].
细胞实验	Briefly， viable cells， as judged by trypan blue dye exclusion， are seeded at a density of 4×104 cells/mL in 60-mm dishes in RPMI 1640 with 10% fetal bovine serum and 0.35% agarose on a base layer of 0.7% agarose. DMSO， TSA， or PB is added to both bottom and top agarose layers. Assays are performed in triplicate on at least three separate occasions， and colonies are counted at 10-14 days[1].
动物实验	Mice[3]Female 10-week-old C57BL/6J mice are housed in the pathogen-free animal facility of IRC. Animals are randomized into the following 4 groups: vehicle control (n=5)， vehicle+Benzenebutyric acid (n=6)， LPS (n=6)， and LPS+Benzenebutyric acid (n=6). Mice are treated with LPS in 200 μL phosphate-buffered saline (PBS) once a week (5 mg/kg， i.p.) for 3 weeks. Benzenebutyric acid solution is prepared by titrating equimolecular amounts of Benzenebutyric acid and sodium hydroxide to reach pH 7.4; mice are injected daily intraperitoneally in 200 μL PBS (or with PBS as a vehicle) at a dose of 240 mg/kg for 3 weeks. Mice are sacrificed by CO2 asphyxiation. To determine the bone mineral density (BMD) and microarchitecture of the long bone， the right femur is scanned. Scans are performed with an effective detector pixel size of 6.9 μm and a threshold of 77-255 mg/cc. Trabecular bone is analyzed in a region 1.6 mm in length and located 0.1 mm below the distal femur growth plate[3].
数据来源文献	[1]. Chang TH， et al. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res. 2002 Apr;8(4):1206-12 [2]. Frouco G， et， al. Sodium phenylbutyrate abrogates African swine fever virus replication by disrupting the virus-induced hypoacetylation status of histone H3K9/K14. Virus Res. 2017 Oct 15;242:24-29. [3]. Park HJ， et al. 4-Phenylbutyric acid protects against lipopolysaccharide-induced bone loss by modulating autophagy in osteoclasts. Biochem Pharmacol. 2018 May;151:9-17.
规格	100mg 500mg
单位	瓶